Amanta Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Amanta Healthcare Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $6.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amanta Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $6.4M Trade | TransData Nexus

Amanta Healthcare Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $6.4M Total Trade · DGFT Verified

Amanta Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $6.4M across 2 products in 2 therapeutic categories. Based on 165 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metronidazole ($4.4M), Salbutamol ($2.0M), .

Amanta Healthcare Limited — Export Portfolio & Destination Treemap

Amanta Healthcare Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Amanta Healthcare Limited? — Company Overview & Market Position

Amanta Healthcare Limited, established in December 1994 as Marck Parenterals (India) Limited, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid pharmaceutical products and medical devices. The company underwent a name change to Marck Biosciences Limited in November 2005 and subsequently to Amanta Healthcare Limited in June 2014. Headquartered in Ahmedabad, Gujarat, India, Amanta Healthcare operates with an authorized capital of ₹90.15 crore and a paid-up capital of ₹38.83 crore. The company employs approximately 522 individuals, reflecting its substantial workforce dedicated to its diverse operations. Amanta Healthcare is publicly listed on the National Stock Exchange of India under the ticker symbol AMANTA.

What Does Amanta Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metronidazole$4.4M 2Salbutamol$2.0M

Product Portfolio — Top 2 by Export Value

Amanta Healthcare Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metronidazole	Advanced Antibiotics	$4.4M	122	2.2%	7
2	Salbutamol	Respiratory	$2.0M	43	1.3%	7

Amanta Healthcare Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $6.4M. The top category is Advanced Antibiotics (68.8% of portfolio), followed by Respiratory (31.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Amanta Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Amanta Healthcare's manufacturing facilities are strategically located in Kheda, Gujarat, India. These plants are designed to meet the stringent requirements of regulated markets, ensuring high-quality production standards. The facilities are equipped with specialized production lines for both Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), utilizing advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company's manufacturing capabilities encompass a wide range of products, including fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices.

3Key Leadership

Amanta Healthcare is led by a team of experienced professionals committed to driving the company's growth and innovation. Bhavesh Patel serves as the Chief Executive Officer (CEO), overseeing the company's strategic direction and operations. Paras Mehta holds the position of Chief Financial Officer (CFO), responsible for managing the company's financial strategies and performance. Anil Rathi serves as the Chief Operating Officer (COO), focusing on optimizing operational efficiency and effectiveness. Additionally, Nikhita Dipesh Dinodia acts as the Company Secretary, ensuring compliance with regulatory requirements and corporate governance standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Amanta Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Amanta Healthcare has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have been inspected and approved by various international regulatory authorities, such as the Therapeutic Goods Administration (TGA) of Australia and the Medicines Control Council (MCC) of South Africa. These approvals underscore Amanta Healthcare's commitment to adhering to global quality standards. The company's product portfolio, which includes fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices, aligns with the therapeutic needs of these markets, facilitating access and acceptance. Amanta Healthcare's strategic focus on innovation and quality has enabled it to navigate the complexities of these regulated markets effectively.

2Emerging Markets

Amanta Healthcare has made strategic inroads into emerging markets, including Africa, Latin America, and Southeast Asia. The company's diverse product portfolio, encompassing fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices, positions it well to meet the healthcare needs of these regions. While specific details regarding WHO prequalification are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a strong foundation for accessing and expanding in these emerging markets. Amanta Healthcare's focus on innovation and quality continues to drive its growth and presence in these regions.

Amanta Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Amanta Healthcare's engagement with the U.S. Food and Drug Administration (FDA) is a critical aspect of its regulatory compliance and market access strategy. The company's manufacturing facilities have been inspected and approved by various international regulatory authorities, including the TGA of Australia and the MCC of South Africa. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a strong foundation for potential FDA engagement. Amanta Healthcare's commitment to quality and regulatory compliance positions it favorably for future interactions with the FDA.

2WHO & EU GMP

Amanta Healthcare's commitment to quality is evident in its manufacturing practices, which adhere to international standards. The company's facilities have been inspected and approved by various international regulatory authorities, including the TGA of Australia and the MCC of South Africa. While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a strong foundation for compliance with WHO and EU GMP requirements. Amanta Healthcare's focus on innovation and quality continues to drive its growth and presence in regulated markets.

Amanta Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Amanta Healthcare operates in a competitive landscape characterized by numerous pharmaceutical companies offering similar products. While specific market share data for Amanta Healthcare's overlapping categories is not publicly disclosed, the company's focus on sterile liquid products and medical devices positions it in direct competition with both domestic and international players. The company's strategic emphasis on innovation, quality, and regulatory compliance provides a competitive edge in the market. Amanta Healthcare's diverse product portfolio and manufacturing capabilities enable it to cater to a wide range of therapeutic segments, enhancing its competitiveness.

2Key Differentiators

Amanta Healthcare's key differentiators include its diverse product portfolio, encompassing fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices. The company's manufacturing facilities utilize advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM), ensuring high-quality production standards. Additionally, Amanta Healthcare's commitment to innovation and quality positions it as a versatile contract manufacturing partner, capable of developing customized solutions for its clients.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Amanta Healthcare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Amanta Healthcare's track record as a supplier is characterized by its adherence to international quality standards and regulatory approvals. The company's export volume and consistency, as evidenced by its total export value of $6.4 million USD from 165 shipments, reflect its reliability and commitment to meeting market demands. Amanta Healthcare's focus on innovation and quality continues to drive its growth and presence in both domestic and international markets.

2Certifications to Verify

Importers should verify the following certifications when engaging with Amanta Healthcare:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Amanta Healthcare Limited

How many pharmaceutical products does Amanta Healthcare Limited export from India?

Amanta Healthcare Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Metronidazole ($4.4M), Salbutamol ($2.0M). Total export value is $6.4M.

What is Amanta Healthcare Limited's total pharmaceutical export value?

Amanta Healthcare Limited's total pharmaceutical export value is $6.4M, based on 165 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Amanta Healthcare Limited cover?

Amanta Healthcare Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (68.8%, 1 products), Respiratory (31.2%, 1 products).

Get Full Amanta Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.